HUTCHMED (China) Limited - American Depositary Shares (NQ:HCM)

13.89 +0.41 (+3.04%)

Delayed Quote Updated: 11:30 AM EDT, Oct 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about HUTCHMED (China) Limited - American Depositary Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Which Chinese Stocks Will Be Delisted? 8 in U.S. Crosshairs ↗

March 28, 2022

As these Chinese stocks face delisting, some may provide a contrarian play on improving relations between the U.S. and China.

Via InvestorPlace

Which Chinese Stocks Could Get Delisted? 6 Companies to Watch. ↗

March 25, 2022

Today, news that Weibo has been added to the SEC's list of at-risk companies for delisting has investors selling Chinese stocks in a big way.

Via InvestorPlace

Chinese Stock Delisting News: Why Are BABA, DIDI, IQ, YUMC, ACMR, BGNE and ZLAB Down Today? ↗

March 11, 2022

Chinese stock delisting news today has several big names in the country seeing their shares slip on fears they could be next.

Via InvestorPlace

What's Going On With Zai Lab, Hutchmed, BeiGene Shares Today ↗

March 11, 2022

Three of the most major drugmakers with roots in China, Zai Lab Ltd (NASDAQ: ZLAB), BeiGene Ltd (NASDAQ: BGNE), and Hutchmed China Ltd (NASDAQ: HCM...

Via Benzinga

Stocks That Hit 52-Week Highs On Thursday ↗

July 29, 2021

Thursday's morning session saw 167 companies set new 52-week highs. Points of Interest: ASML Holding (NASDAQ:ASML) was the largest company by market cap to set a new...

Via Benzinga

The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗

March 13, 2022

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments...

Via Benzinga

Hutchmed Roils Markets With Changing of Its Guard, U.S. Delisting Threat ↗

March 11, 2022

Key Takeaways U.S. securities regulator says Hutchmed is one of five Chinese companies in danger of delisting, a week after company announced the retirement of its longtime CEO...

Via Benzinga

Chinese Stocks Are Falling: What's Going On? ↗

March 10, 2022

Shares of multiple Chinese companies are trading lower Thursday following reports the U.S. Securities and Exchange Commision has identified multiple US-listed ADRs as...

Via Benzinga

Why BeiGene — And 2 Other China-Based Biotechs — Are In Trouble ↗

March 10, 2022

The SEC is calling out a several stocks for non-compliance. Could they face delisting?

Via Investor's Business Daily

Hutchmed Clocks Over 50% Jump In FY21 Sales Boosted By Three Oncology Drugs, Announces CEO Transition ↗

March 03, 2022

Hutchmed (China) Limited (NASDAQ: HCM) reported FY21 sales of $356.1 million, up 56% Y/Y, driven by commercial progress on three in-house developed oncology drugs...

Via Benzinga

Week In Review: Biopharma Deals Slow During Chinese New Year Week ↗

February 05, 2022

Amid a slow week, Shanghai's HanBio Therapeutics raised $40 million in a Series A financing to advance its innovative biologic products. HanBio is an early R&D company that was incubated by Sunshine...

Via Talk Markets

31 Stocks Moving In Thursday's Mid-Day Session ↗

December 16, 2021

Gainers Calliditas Therapeutics AB (NASDAQ: CALT) shares climbed 28.7% to $24.13 after the company announced it was granted by the FDA accelerated approval of TARPEYO to reduce...

Via Benzinga

Earnings Scheduled For March 3, 2022 ↗

March 03, 2022

Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban...

Via Benzinga

58 Biggest Movers From Yesterday ↗

December 17, 2021

Gainers Adagio Therapeutics, Inc. (NASDAQ: ADGI) shares jumped 123.3% to settle at $14.18 on Thursday after traders circulated rumors of a reiterated Buy rating and $46 price...

Via Benzinga

18 Stocks Moving in Thursday's Pre-Market Session ↗

December 16, 2021

Gainers Calliditas Therapeutics AB (NASDAQ: CALT) rose 36.5% to $25.45 in pre-market trading after the company announced it was granted by the FDA accelerated approval of TARPEYO...

Via Benzinga

61 Biggest Movers From Yesterday ↗

November 23, 2021

Gainers Longeveron Inc. (NASDAQ: LGVN) shares surged 181.2% to settle at $28.20 on Monday on continued upward momentum after the company last week announced the FDA granted Rare...

Via Benzinga

40 Stocks Moving In Monday's Mid-Day Session ↗

November 22, 2021

Gainers iSpecimen Inc. (NASDAQ: ISPC) shares climbed 126.5% to $11.12 after the company announced it has been contracted to support new advanced research on COVID-19 seeking...

Via Benzinga

20 Stocks Moving in Monday's Pre-Market Session ↗

November 22, 2021

Gainers Astra Space, Inc. (NASDAQ: ASTR) rose 39.6% to $13.30 in pre-market trading after declining around 3% on Friday. Astra Space recently reported a Q3 loss of $0.06 per...

Via Benzinga

Week In Review: Broncus Stages $200 Million Hong Kong IPO For Pulmonary Devices ↗

September 25, 2021

Broncus Holding, a Hangzhou pulmonary medical device company, completed a $200 million IPO on the Hong Kong exchange that valued the company at nearly $1.3 billion. The IPO was priced at the top end of...

Via Talk Markets

Topics Initial Public Offering

HUTCHMED's Lymphoma Candidate Secures Breakthrough Tag In China ↗

September 13, 2021

The Center for Drug Evaluation of China's National Medical Products Administration has granted Breakthrough Therapy Designation to HUTCHMED (China) Limited...

Via Benzinga

Week In Review: RemeGen Out-Licenses Rights For HER2 ADC To Seagen In $2.6 Billion Deal ↗

August 14, 2021

Yantai's RemeGen out-licensed global rights (ex-Asia) for its novel HER2-targeted ADC to Seagen in a $2.6 billion deal. Seagen, an antibody conjugate company, will pay $200 million upfront and up to...

Via Talk Markets

The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod ↗

September 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc...

Via Benzinga

Epizyme Stock Gains On Potential $310M Pact With HUTCHMED For Cancer-Focused Tazverik In Greater China ↗

August 09, 2021

Epizyme Inc (NASDAQ: EPZM) and HUTCHMED (China) Limited (NASDAQ: HCM) have collaborated to research, develop, manufacture, and commercialize Tazverik (...

Via Benzinga

Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China

August 08, 2021

From Epizyme, Inc.

Via Business Wire

62 Biggest Movers From Yesterday ↗

July 29, 2021

Gainers Flora Growth Corp. (NASDAQ: FLGC) surged 63.1% to close at $8.27. The Miami-based cannabis producer confirmed Tuesday it has signed a non-binding letter of intent to...

Via Benzinga

Topics Cannabis

Hutchison China MediTech Ltd (HCM) Q2 2021 Earnings Call Transcript ↗

July 28, 2021

HCM earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

50 Stocks Moving In Wednesday's Mid-Day Session ↗

July 28, 2021

Gainers Infinity Pharmaceuticals Inc. (NASDAQ: INFI) shares jumped 59.9% to $2.43. Infinity Pharmaceuticals shares tumbled over 31% on Tuesday after the company highlighted the...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

July 28, 2021

Gainers Infinity Pharmaceuticals (NASDAQ:INFI) shares moved upwards by 40.13% to $2.13 during Wednesday's pre-market session. The company's market cap stands at $...

Via Benzinga

Hutchmed Stock Gains On Kick Starting Mid-Stage Gastric Cancer Trial With AstraZeneca's Orpathys ↗

July 28, 2021

HUTCHMED (China) Limited (NASDAQ: HCM) and AstraZeneca Plc (NASDAQ: AZN) have initiated a Phase 2 study of Orpathys (savolitinib) in patients with...

Via Benzinga

28 Stocks Moving in Wednesday's Pre-Market Session ↗

July 28, 2021

Gainers Infinity Pharmaceuticals Inc. (NASDAQ: INFI) shares rose 38.2% to $2.10 in pre-market trading. Infinity Pharmaceuticals shares tumbled over 31% on Tuesday after the...

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.